Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASALONDON: Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo’s drugs.
The Danish company said it filed the lawsuit in U.S. District Court in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.
Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.
Novo said it is seeking a court order requiring Lilly to withdraw the advertisements and run a corrective advertising campaign. It added that it plans to seek a preliminary injunction if Lilly does not voluntarily remove the ads.
Novo Nordisk cuts Wegovy price in South Africa for a second time
Novo said it sent Lilly a cease-and-desist letter in April after the U.S. approved a 7.2-milligram dose of Wegovy. Lilly did not respond to the letter, Novo’s general counsel John Kuckelman told Reuters, adding that the company instead inserted what he described as an inadequate disclaimer into the advertisements.
Kuckelman said Lilly’s advertisements compare weight-loss results of about 50 pounds for Zepbound with about 33 pounds for Wegovy, even though no head-to-head trial has compared the highest approved doses of the medicines. He said separate late-stage trials of the highest doses showed average weight loss of about 48 pounds for Zepbound and 47 pounds for Wegovy.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads | 0 | 7 | 21-07-2026 |
| 2 | Novo Nordisk’s obesity drug Wegovy gets CDSCO approval to treat liver condition | 5 | 7 | 17-07-2026 |
| 3 | Weight‑loss jabs may create a new kind of yo‑yo dieting | 0 | 7 | 10-07-2026 |
| 4 | Most obesity drugs do not improve quality of life or heart health, analysis indicates | -2 | 7 | 08-07-2026 |
| 5 | GLP-1 use hits record high as Medicare opens access to weight-loss drugs | 0 | 7 | 09-07-2026 |
| 6 | Novartis profit beat driven by cost control as patent expiries bite | 0 | 7 | 21-07-2026 |
| 7 | DRL’s semaglutide supply hits a stumbling block, affects other companies too | 0 | 5 | 09-07-2026 |
| 8 | Women more often hired after losing weight on GLP-1s: Study | 0 | 5 | 03-07-2026 |
| 9 | Granules India's first-quarter profit surges as margins improve | 5 | 7 | 21-07-2026 |
| 10 | Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims | 0 | 7 | 30-06-2026 |